Navigation Links
The 4th Annual BIO Investor Forum to Webcast Alexza's Corporate Presentation
Date:10/3/2007

PALO ALTO, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate presentation will be webcast live during the 4th Annual BIO Investor Forum on Thursday, October 11, 2007 at 4:30 p.m. Eastern Time. The presentation will be webcast from The Palace Hotel, San Francisco and may be accessed under the Investor Relations tab at http://www.alexza.com or http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ALXA&item_id=16576 53. The presentation will be archived for 14 days.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has six product candidates in development; AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic and bipolar disorder patients, AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches, AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain and AZ-007 (Staccato zaleplon) for the treatment of sleep disorder in patients who have difficulty falling asleep.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2006, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NameProtect releases annual list of top trademarkers
2. Doyle says new contracts saving state more than $16 million annually
3. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
4. Annual Bioethics Forum to explore genetic testing
5. Annual Conference Honors Tech Grant Winners
6. Venture Investors early-stage fund grows to $115 million
7. Investor warns of angel-venture funding gap
8. Brazilian bio-industry should impress American investors
9. Investors raise $25 million for biodiesel plant
10. Bio-energy and cleantech grab attention of investors
11. Venture Investors to open Michigan office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program to hire college athletes, ... for attitude. Train for skill.” , In keeping with this philosophy, the Catalyst an ... salesman. Zamzow is hoping to replicate the practice throughout the company. , “I’ve heard ...
(Date:2/24/2017)... ... , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today ... (NIMH) for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). ... deliver therapeutic levels of olanzapine for a period of 3 months., “We are honored ...
(Date:2/24/2017)... PARSIPPANY, N.J. , Feb. 24, 2017 /PRNewswire/ ... botanicals and biotechnology are now the fastest growing ... the Specialty Actives in Personal Care: Multi-regional ... market research and management consulting firm Kline. ... using bioprocesses that make them more effective for ...
(Date:2/24/2017)... SAN DIEGO , Feb. 24, 2017  OncoSec ... intratumoral cancer immunotherapies, will host a Key Opinion Leader ... featured as an oral and poster presentation at the ... development plan. The KOL event will be held in-person ... 12:00 PM EST / 9:00 AM PST at the ...
Breaking Biology Technology:
(Date:2/6/2017)... 6, 2017 According to Acuity Market ... border authorities to continue to embrace biometric and ... 2143 Automated Border Control (ABC) eGates and 1436 ... more than 163 ports of entry across the ... achieving a combined CAGR of 37%. APC Kiosks ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
(Date:1/26/2017)... -- Acuity Market Intelligence today released the 2017 "Ten ... characterizes 2017 as a "breakout" year for biometrics ... new understanding of the potential benefits these technologies ... are often perceived as threats to privacy and ... Acuity Market intelligence. "However, taken together these technologies ...
Breaking Biology News(10 mins):